Market Overview

Zogenix Shares Rally as FDA Redschedules Hydrocodone Drugs Panel

Related ZGNX
Zogenix Reports Zohydro ER Shows Sustained 12-Hour Pain Relief
Zohydro Gains Massachusetts Approval, Acts As Minor Catalyst For Zogenix

Shares of Zogenix (NASDAQ: ZGNX) rallied more than 10 percent on Tuesday following news the FDA rescheduled an advisory panel for hydrocodone drugs to January 24th-25th.

View pdf.

Posted-In: News FDA Movers

 

Related Articles (ZGNX)

Around the Web, We're Loving...

Get Benzinga's Newsletters